ARQT vs EXEL
Arcutis Biotherapeutics, Inc. vs Exelixis — AI-powered side-by-side comparison
ARQT
Arcutis Biotherapeutics, Inc.
64
Buy
VS
| Metric | ARQT | EXEL |
|---|
| AI Score |
64
|
67
|
| Price |
$26.21
|
$51.30
|
| P/E Ratio |
118.80×
|
15.60×
|
| ROE |
-8.5%
|
36.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
96.5%
|
| Debt / Equity |
0.52×
|
0.09×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
44.7
|
41.0
|
| Beta |
1.526
|
0.422
|
| Expected Upside |
—
|
+8.7%
|
AI Committee View
Current Innellis committee reasoning for ARQT versus EXEL.
EXEL leads by 3 points.
EXEL scores 67/100 (Buy) versus ARQT at 64/100 (Buy).
ARQT Committee View
60% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 15.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 114.1 is expensive by classic value standards — Value
- Price-to-book of 18.8x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical